Most interlocutory decisions under the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) are made by prothonotaries of the Federal Court (FC). Under the pre-amended PMNOC Regulations, a party was permitted to appeal any such decision to a FC judge, as of right and a further appeal could be made to the Federal Court of Appeal (FCA), also as of right. Under the amended PMNOC Regulations (see our article here), any appeal of an interlocutory order made by a prothonotary or judge of the FC must be heard by the FCA, and only if the FCA grants leave.
The first FCA decision in an appeal of an interlocutory order under the amended PMNOC Regulations issued on June 27, 2019. The FCA dismissed Apotex’s appeal of a prothonotary’s decision declining to order Bristol-Myers Squibb (BMS) to answer five discovery questions in an action relating to apixaban (BMS’ ELIQUIS): Apotex v Bristol-Myers Squibb Canada, 2019 FCA 194. The questions generally related to BMS’ pleading alleging e.g. “advantages and benefits” of apixaban, as disclosed and claimed in the patent at issue. The FCA found that the Prothonotary was entitled to arrive at a view of what was best for the particular proceeding and saw no reviewable error that would justify its intervention.
Related Publications & Articles
-
Supreme Court of Canada dismisses Apotex’s application for leave to appeal macitentan inducing infringement decision
On June 6, 2024, the Supreme Court of Canada dismissed Apotex’s application for leave to appeal (Docket No. 41087).Read More -
Supreme Court of Canada dismisses Apotex and Pharmascience’s applications for leave to appeal paliperidone inducing infringement decisions
On June 27, 2024, the Supreme Court of Canada dismissed Apotex and Pharmascience’s applications for leave to appeal (Docket Nos. 41162 and 41164).Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More